Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
CYSTIC FIBROSIS SCREEN, PCR |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2162 Geisinger Epic ID: 54553 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole blood | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL pink-top K2 EDTA tube
|
|
Specimen required: |
3 mL lavender EDTA whole blood; minimum 0.5 mL. NO SHARED SPECIMENS WITH OTHER LABORATORY DEPARTMENTS. May be combined with other Molecular Diagnositic tests. For genetic testing, original tube required. | |
Special notes: |
|
|
SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge. | |
Transport temperature: |
Refrigerated: 2-8°C. | |
Specimen stability: |
Refrigerated (2-8°C): 4 weeks. | |
Rejection criteria: |
Specimen collected in heparin (green-top) tube will be rejected. Frozen whole blood specimens will be rejected. Stability limits exceeded. Shared or comingled specimens. | |
TEST DETAILS |
||
Reference interval: |
Negative. | |
Additional information: |
For genetic testing, original tube required. | |
CPT code(s): |
81220 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
ACMG recommended 23 mutation panel: DeltaF508, G542X, R553X, R117H, 711+1G>T, R347P, DeltaI507, 1717-1G>A, R560T, A455E, 2789+5G>A, W1282X, R334W, N1303K, G85E, 3849+10kbC>T, 1898+1G>A, R1162X, 2184delA, 3120+1G>A, G551D, 621+1G>T, and 3659delC. | |
Methodology: |
Multiplex polymerase chain reaction (PCR) GenMark Dx eSensor Technology |
|
Synonyms: |
CF PCR, cystic fibrosis, cystic fibrosis PCR, cystic fibrosis mutation, CF mutation, CF genotype, cystic fibrosis genotype, CF DNA, cystic fibrosis DNA, CFTR, cystic fibrosis transmembrane conductance. CFSCRE
|
|
Clinical significance: |
This test is used for cystic fibrosis (CF) carrier screening in adults of reproductive age, newborn CF screening, and for confirmatory diagnosis of CF in newborns and children. | |
Doctoral Director(s:) |
Yi Ding MD, PhD | |
Review Date: | 12/20/2022 |